April 16, 2018 / 12:20 PM / 5 days ago

BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

April 16 (Reuters) - XBiotech Inc:

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

* XBIOTECH INC - CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES

* XBIOTECH INC - UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below